Ginkgo Bioworks

Update in progress

DNA (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Ginkgo Bioworks and its subsidiaries operate a platform for cell engineering in the United States, with two segments: Cell Engineering and Biosecurity. It provides R&D solutions and tools for functional genomics, developability of antibodies and small molecules, AI models, and reconfigurable automation for engineered organisms and products. Canopy offers biomonitoring and bioinformatics, while Horizon covers digital surveillance and biothreat monitoring. Founded 2008, based in Boston.

Company score

Sentiment: 0.79; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.55; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.50; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.37; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.58; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive